These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 7522176

  • 41. [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding.
    Seiler SM, Brassard CL, Federici ME, Romine J, Meanwell NA.
    Prostaglandins; 1997 Jan; 53(1):21-35. PubMed ID: 9068064
    [Abstract] [Full Text] [Related]

  • 42. Activation of the prostaglandin EP4-receptor subtype is highly coupled to inhibition of N-formyl-methionyl-leucyl-phenylalanine-stimulated rat neutrophil aggregation.
    Wise H.
    Prostaglandins Leukot Essent Fatty Acids; 1998 Jan; 58(1):77-84. PubMed ID: 9482170
    [Abstract] [Full Text] [Related]

  • 43. Functional characterization of the prostanoid DP receptor in human myometrium.
    Fernandes B, Crankshaw D.
    Eur J Pharmacol; 1995 Sep 05; 283(1-3):73-81. PubMed ID: 7498323
    [Abstract] [Full Text] [Related]

  • 44. Homologous desensitization of human platelet thromboxane A2/prostaglandin H2 receptors.
    Okwu AK, Ullian ME, Halushka PV.
    J Pharmacol Exp Ther; 1992 Jul 05; 262(1):238-45. PubMed ID: 1378092
    [Abstract] [Full Text] [Related]

  • 45. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Szalkowski DM, MacIntyre DE, Bach TJ, Luell S, Meuer R, Sahoo SP, Alberts AW, Chabala JC.
    J Lipid Mediat; 1993 Jun 05; 7(2):115-34. PubMed ID: 8400114
    [Abstract] [Full Text] [Related]

  • 46. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor.
    Merritt JE, Brown AM, Bund S, Cooper DG, Egan JW, Hallam TJ, Heagerty AM, Hickey DM, Kaumann AJ, Keen M.
    Br J Pharmacol; 1991 Jan 05; 102(1):260-6. PubMed ID: 2043927
    [Abstract] [Full Text] [Related]

  • 47. Histamine inhibits activation of human neutrophils and HL-60 leukemic cells via H2-receptors.
    Burde R, Seifert R, Buschauer A, Schultz G.
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Dec 05; 340(6):671-8. PubMed ID: 2559336
    [Abstract] [Full Text] [Related]

  • 48. Effect of etizolam (Depas) on production of superoxide anion by platelet-activating factor and N-formyl-methionyl-leucyl-phenylalanine-stimulated guinea pig polymorphonuclear leukocytes.
    Aratani H, Nishida Y, Terasawa M, Maruyama Y.
    Jpn J Pharmacol; 1988 Jun 05; 47(2):200-3. PubMed ID: 2848961
    [Abstract] [Full Text] [Related]

  • 49. Pharmacology of functional endogenous IP prostanoid receptors in NCB-20 cells: comparison with binding data from human platelets.
    Crider JY, Xu SX, Sharif NA.
    Prostaglandins Leukot Essent Fatty Acids; 2001 Jun 05; 65(5-6):253-8. PubMed ID: 11993717
    [Abstract] [Full Text] [Related]

  • 50. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
    Haslam RJ, Davidson MM, Desjardins JV.
    Biochem J; 1978 Oct 15; 176(1):83-95. PubMed ID: 215136
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. A new prostacyclin analog, KP-10614, inhibits platelet-polymorphonuclear leukocyte interaction and limits experimental infarct size in rat heart.
    Kanayama T, Kimura Y, Mizogami S.
    J Pharmacol Exp Ther; 1993 Jul 15; 266(1):344-9. PubMed ID: 7687292
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
    Liao CH, Cheng JT, Teng CM.
    Eur J Pharmacol; 2005 Sep 05; 519(1-2):158-67. PubMed ID: 16112105
    [Abstract] [Full Text] [Related]

  • 55. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.
    Naka M, Mais DE, Morinelli TA, Hamanaka N, Oatis JE, Halushka PV.
    J Pharmacol Exp Ther; 1992 Aug 05; 262(2):632-7. PubMed ID: 1386885
    [Abstract] [Full Text] [Related]

  • 56. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV.
    Bevilacqua M, Vago T, Baldi G, Renesto E, Dallegri F, Norbiato G.
    Eur J Pharmacol; 1994 Aug 16; 268(3):415-23. PubMed ID: 7805766
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Occupancy of P2 purinoceptors with unique properties modulates the function of human platelets.
    Soslau G, Brodsky I, Parker J.
    Biochim Biophys Acta; 1993 Jun 06; 1177(2):199-207. PubMed ID: 7684612
    [Abstract] [Full Text] [Related]

  • 59. Magnesium modifies the responses of platelets to inhibitory agents which act via cAMP.
    Hardy E, Glenn J, Heptinstall S, Rubin PC, Horn EH.
    Thromb Haemost; 1995 Oct 06; 74(4):1132-7. PubMed ID: 8560425
    [Abstract] [Full Text] [Related]

  • 60. Inhibitory effects of 16-hydroxycleroda-3,13(14)E-dien-15-oic acid on superoxide anion and elastase release in human neutrophils through multiple mechanisms.
    Chang HL, Chang FR, Chen JS, Wang HP, Wu YH, Wang CC, Wu YC, Hwang TL.
    Eur J Pharmacol; 2008 May 31; 586(1-3):332-9. PubMed ID: 18367166
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.